Online ISSN: 2515-8260

Keywords : Itraconazole


A Clinico-Mycological and Therapeutic Study of Recurrent Dermatophytic Infections and Determining the Right Dose and Duration of Systemic Antifungals

Dr Puneet Singh Soodan, Dr Avneet Kaur, Dr Nikita Soodan

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 1, Pages 789-796

Aim: To analyse clinico-mycological and therapeutic study of recurrent dermatophytic
infections and determining the right dose and duration of systemic antifungals.
Material and methods: This randomized controlled trial was conducted at the
department of DVL, Acharya Shri Chander College of Medical Sciences, Jammu from
January 2021 - May 2021 among 90 patients with superficial cutaneous fungal infection
coming to the dermatology OPD. Selected 90 patients were assigned to a trial group and
given the standard dose of the drug i.e. Tab. Itraconazole (100mg OD), Tab.
Griseofulvin (250mg BD) and Tab. Terbinafine (250mg OD). Evaluation was done by
clinical assessment in terms of clinical score. The clinical signs and symptoms assessed
were scaling, erythema, and pruritus.
Results: Tinea corporis was the principal dermatophytic lesion accounted for 93.33% of
the study subjects. Pruritus, Erythema, scaling and total scores reduced significantly in
all the drugs i.e. Griseofulvin, Itraconazole and Terbinafine. However reduction was
reported more in Itraconazole drug in our study. Complete clinical cure was reported in
3.33%, 70% and 26.67% of the subjects in Itraconazole drug at 1st visit (3w), 2nd visit
(6w) and 3rd visit (9w) respectively. No cure was reported in Griseofulvin and
Terbinafine drug at 1st visit (3w). 23.33%, 76.67% and 6.67%, 43.33% of the subjects
in Griseofulvin and Terbinafine drug were completely cured at 2nd visit (6w) and 3rd
visit (9w) respectively.
Conclusion: Itraconazole was found to be the best drug for the treatment of
dermatophytes among the tested antifungals.

Recent Modality in the Treatment of Recalcitrant Dermatophytosis

Fathia Mohamed Khattab, MD; Aya Abd-Elbaset, Msc; Mohamed Taha, MD; Basma Magdy Elkholy, MD

European Journal of Molecular & Clinical Medicine, 2021, Volume 8, Issue 3, Pages 3771-3777

Background:Dermatophytosis is a common skin diseasein Egypt. It iscaused by
keratinophilic fungi. Tinea become chronic, recurrent and resistant to traditional
therapies. Isotretinoin is a good adjuvant to systemic antifungal in chronic
dermatophytosis due to its keratolytic effect.
Aim: This is a prospective study to assess the effectiveness of combined oral
itraconazole/isotretinoin therapyin the treatment of chronic and recalcitrant
dermatophytosis.
Patients and Methods:A total of 30 patients with chronic and/or recalcitrant
dermatophytosis were included. Potassium hydroxide microscopy was performed.All
the patients received combined oral itraconazole/isotretinoin therapy;Itraconazole
200 mg twice daily with adjuvant isotretinoin20 mg dailyfor 6 weeks. The patients
were followed up to 6 monthsfor signs of recurrence.
Results:Mycological cure was observed in83.3% andcomplete cureoccurred in 70%
of the patients.
Conclusions: Combined oral itraconazole/isotretinoin therapycould be an effective
treatment in recalcitrant dermatophytosis.